Examples include HER2-derived peptides (E75, AE37, and GP2) in breast cancer (65–67) and gp100 or MART-1 peptides in melanoma, which have induced antigen-specific T-cell responses in early-phase investigations (68, 69). This evidence concerns the gene ERBB2 and breast carcinoma.